Holen Sie sich die Stockscreener-App
376.44
1.15%
-3.6819
Schlusskurs vom Vortag:
$380.12
Offen:
$380
24-Stunden-Volumen:
22,669
Relative Volume:
0.08
Marktkapitalisierung:
$10.08B
Einnahmen:
$2.59B
Nettoeinkommen (Verlust:
$168.80M
KGV:
61.97
EPS:
6.0748
Netto-Cashflow:
$357.20M
1W Leistung:
-3.28%
1M Leistung:
+6.61%
6M Leistung:
+38.43%
1J Leistung:
+31.41%
1-Tages-Spanne:
$373.34
$380.00
1-Wochen-Bereich:
$373.34
$394.29
52-Wochen-Spanne:
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
376.92 | 10.16B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
106.17 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.84 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.97 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.62 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.51 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - Manufacturing Chemist
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Bio-Rad Laboratories (BIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - cambridgenetwork.co.uk
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? - Yahoo Finance
Westport Asset Management Inc. Invests $881,000 in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 By Investing.com - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 - Investing.com
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
S&P 500 Futures Decline In Premarket Trading; Bio-Rad Labs A, Fabrinet Lag - Moomoo
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with Innovative Diagnostics - DirectorsTalk Interviews
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - aol.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):